This page addresses one specific transaction under New York law: a beneficiary buying real or personal property from a trust at fair value — that is, paying the trust for an asset rather than simply receiving it as a distribution. The rules here are different from those that apply when a beneficiary lives in an inherited house, when co-owners pursue a buyout of an inherited residence, or when an heir is borrowing against inherited property. If you are trying to understand your right to financial records, see a beneficiary's rights to trust information. This page focuses narrowly on the purchase itself, the self-dealing analysis, fair-market-value proof, and Surrogate's Court approval.
A New York trustee's authority to sell trust property is governed primarily by the Estates, Powers and Trusts Law (EPTL) and the trust instrument itself. Under EPTL 11-1.1(b)(5), a fiduciary generally has the power to sell trust property at public or private sale unless the will or trust restricts that power. The trustee must exercise that power consistent with the fiduciary duties codified throughout EPTL Article 11 and developed in New York case law — principally the duties of loyalty, impartiality, and prudence.
Before assuming a sale to a beneficiary is permitted, read the trust instrument. A trust may (1) authorize sales generally, (2) prohibit sale of a specific asset (for example, requiring that a family home pass to a named beneficiary in kind), (3) require the trustee to obtain beneficiary consent or a co-trustee's joinder, or (4) restrict sales to particular persons. Where the instrument is silent, EPTL 11-1.1 supplies the default power to sell.
Separately, the property cannot be sold if a court order restrains it — for example, a lien (the sale would be subject to the lien), or a preliminary injunction or temporary restraining order issued in a contested Surrogate's Court or Supreme Court proceeding.
The central legal issue in any trust-to-beneficiary sale is the duty of loyalty. New York follows the strict no-further-inquiry rule for self-dealing: when a trustee transacts with the trust on the trustee's own behalf, a court will not inquire into the fairness of the transaction. The transaction is voidable at the option of a beneficiary regardless of how fair the price was, unless the transaction was authorized by the trust instrument, consented to by all beneficiaries after full disclosure, or approved by the court. This rule traces to longstanding New York authority (see Matter of Rothko, 43 N.Y.2d 305 (1977), and the line of cases applying the undivided-loyalty principle) and to the prohibition on a fiduciary profiting from a position of trust.
Whether the no-further-inquiry rule applies depends entirely on who the buyer is:
This is not classic self-dealing. The trustee has no personal financial stake in the transaction beyond ordinary administration, so the no-further-inquiry rule does not automatically void the sale. But the trustee still owes a duty of impartiality to every beneficiary, including those who are not buying. The trustee cannot favor the purchasing beneficiary at the expense of the others. The protection here is proof that the trust received fair market value, that the process was open, and that non-purchasing beneficiaries received notice.
This is the hard case and the one most New York families actually face — a family member who serves as trustee and wants to buy the family home that they also have an interest in as a beneficiary. Because the trustee is on both sides of the deal, the transaction triggers the self-dealing prohibition and the no-further-inquiry rule. A fair price alone will not insulate it. The trustee should secure either (a) the informed written consent of all other beneficiaries, or (b) advance approval from the Surrogate's Court.
When the trustee is also the buyer, or when any beneficiary is likely to object, the prudent course is to obtain court approval before closing. There are two principal procedural routes in New York:
A petition for advance approval typically includes:
The court directs that the other beneficiaries receive citation or notice, hears any objections, and issues a decree approving or rejecting the sale. A sample timeline: drafting and filing the petition (2–4 weeks), citation and the return date for objections (roughly 4–8 weeks depending on the county and method of service), and decision (varies by Surrogate's Court calendar). Contested matters take substantially longer. Counties most relevant to our clients include New York, Kings, Queens, Bronx, and the surrounding Surrogate's Courts.
Whatever route is chosen, fair market value is the evidentiary foundation. The value should be established by methods the other beneficiaries cannot reasonably attack:
Independent appraisal. Retain a licensed appraiser with no relationship to either the trustee or the purchasing beneficiary. Preserve the appraiser's credentials, the effective date, and the methodology.
Comparable sales. Document recent arm's-length sales of similar property in the same market area.
Multiple opinions. For high-value or contentious assets, a second appraisal or broker price opinion strengthens the record.
Open-market test. Listing the property publicly for a defined period and accepting the highest bid — even when the beneficiary is the expected buyer — is the single strongest proof that the price reflects the market. In a self-dealing posture, it can be worth doing for that reason alone.
Not without exposure. Selling trust property to one beneficiary below fair market value shifts value away from the other beneficiaries and breaches the duty of impartiality. Any objecting beneficiary may petition the Surrogate's Court to surcharge the trustee for the shortfall or to set the sale aside. Where the trustee is also the buyer, a below-market sale combines a breach of impartiality with self-dealing — a serious matter. The narrow exceptions are an explicit instruction in the trust instrument, fully informed written consent of every affected beneficiary, or court approval. For the broader principles, see breach of fiduciary duty and breach of trust.
How the beneficiary pays affects how defensible the transaction is:
Seller financing requires careful drafting. The note should bear a market interest rate (below-market interest can create imputed interest and gift-tax issues under the Internal Revenue Code's applicable federal rate rules), include reasonable repayment terms, and be properly secured by a recorded mortgage. An undersecured or below-market loan to a fellow beneficiary — especially one made by a trustee who is also the borrower — can itself be challenged as a breach of the duty of impartiality or as self-dealing. When the trustee is the borrower, court approval of the financing terms is strongly advised before closing.
Even where not strictly required, giving the other beneficiaries advance notice is sound practice and often dispositive. The notice should identify the property and buyer, disclose the price and terms, attach the appraisal, and invite comment or objection within a stated period. Beneficiaries who receive full disclosure and do not object generally cannot complain afterward; those who object before closing give the trustee the chance to address the concern or seek court approval first.
The closing file should preserve every protective step:
Strong documentation makes the transaction defensible; weak documentation leaves the trustee exposed if the sale is later questioned in an accounting.
Generally no, not without risk. A below-market sale to one beneficiary shortchanges the others and breaches the trustee's duty of impartiality. It is permitted only where the trust instrument allows it, all affected beneficiaries give informed written consent, or the Surrogate's Court approves it.
Not always. If the buyer is a beneficiary who is not the trustee, court approval is usually unnecessary when the price is fair and the other beneficiaries are noticed. If the trustee is also the buyer, the self-dealing and no-further-inquiry rules make court approval (or unanimous informed consent) strongly advisable.
Only consistent with the trust terms. If the instrument directs a specific asset to a particular beneficiary in kind, the trustee cannot sell it out from under that beneficiary without consent or court direction.
Objections can be raised before closing or later in a judicial accounting under SCPA Article 22. The Surrogate's Court can approve, modify, or set aside the sale and may surcharge the trustee for any loss caused by an unfair transaction. See inheritance dispute options.
Whether you are a trustee considering a sale to a beneficiary, a beneficiary hoping to purchase trust property, or a beneficiary concerned about a proposed sale, the structure you choose determines your exposure. Our firm handles trust administration and contested trust matters in the New York City Surrogate's Courts. To discuss the specific facts of your trust, contact the Law Offices of Albert Goodwin in New York. Nothing on this page is legal advice or creates an attorney-client relationship; outcomes depend on your specific facts and the terms of your trust.